“The GLP-1 agonists market is highly consolidated with major players formulating strategies to dominate the market. Key players in the GLP-1 agonists market include Novo Nordisk (Denmark), Eli Lilly (USA), and Sanofi (France).”
GLP-1 agonists market by product (Ozempic, Wegovy, Mounjaro), molecule (semagluide, tirzepatide), type (patent, biosimilar), format (single dose, multiple dose, tablets), ROA (SC, oral), indication (diabetes, obesity) – Global Forecast to 2033
global GLP-1 Agonist Marketwas valued at USD 53.74 Billion in 2024, and at USD 64.42 Billion in 2025, and is expected to grow at a CAGR of 13.0% from 2025 to 2033, reaching an estimated value of USD 170.75 Billion by the end of that period. Factors such as expansion in API and fill finish manufacturing are increasing supply capacity to meet surging global demand for these treatments. Indication expansions, such as approvals for additional metabolic and cardiovascular diseases, are expanding patient access and driving adoption. Moreover, with the increasing prevalence of obesity and type 2 diabetes (T2D) across the world, the market demand continues to increase significantly as GLP-1 agonists play a pivotal role in the treatment and management of these diseases.
According to the indication, The GLP-1 agonists market is segmented into diabetes, obesity, and other indications. By 2024, the diabetes segment will dominate the market. GLP-1 agonists are becoming a key drug class in the treatment of diabetes due to their proven benefits for glycemic control, weight loss, and cardiovascular risk mitigation. Diabetes remains the dominant indication in the GLP-1 market due to strong clinical adoption, broad regulatory approval, and significant patient population.
By route of administration, The GLP-1 agonists market is segmented into subcutaneous route and oral route. By 2024, the subcutaneous segment dominated the market. A large share of this market is due to the established efficacy and patient acceptance of GLP-1 agonists, enabling efficient and controlled drug delivery in sustained release. This route of administration allows for an easy to use self-injecting device that improves compliance and convenience.
By regionThe GLP-1 agonists market is segmented into six regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is expected to register the highest growth rate during the forecast period due to high prevalence of obesity and diabetes and rapid adoption of innovative metabolic treatments. A strong healthcare reimbursement framework, robust clinical infrastructure, and early regulatory approvals accelerate product uptake. Additionally, significant investments in manufacturing expansion and extensive marketing efforts by leading pharmaceutical companies are fueling the market momentum in the region.
The GLP-1 agonists market is highly consolidated and key players are strategizing to capture the market. Key players in the GLP-1 agonists market include Novo Nordisk (Denmark), Eli Lilly (USA), and Sanofi (France).
Novo Nordisk (Denmark):
Novo Nordisk is a global leader in metabolic disease innovation, known for pioneering GLP-1 agonists such as semaglutide (Ozempic, Wegovy, Rybelsus), which are transforming the treatment of diabetes and obesity. The company’s strategic roadmap is marked by continued investments in R&D, with a strong late-stage pipeline and recent launches addressing new indications such as cardiovascular risk reduction, chronic kidney disease and metabolic dysfunction-related steatohepatitis (MASH). The company embarked on a major manufacturing expansion to meet surging demand and acquired new production sites to ensure global supply chain resilience. The company leverages cutting-edge technologies such as AI-based drug discovery, innovative formulations, and digital health solutions. Novo Nordisk maintains a strategic position in the fast-growing GLP-1 agonists market with a focus on enhancing scale, innovation and therapeutic reach.
Eli Lilly (USA)
Eli Lilly is another leading company in the GLP-1 agonists market, with its dual-agonist tirzepatide (Mounjaro, Zepbound) significantly driving the growth of obesity and diabetes treatments through 2025. The company is innovating with next-generation oral GLP-1 receptor agonists, such as orfoglyphrone, to eliminate barriers to injection, providing improved patient access and compliance. Eli Lilly is also expanding its manufacturing capacity to ensure strong production and global reach in response to surging demand. Through strategic pipeline diversification to include metabolic and cardiology solutions, as well as competitive pricing and aggressive label expansion, Eli Lilly is uniquely positioned to address market needs and maintain long-term leadership in the GLP-1 segment. This combined effort, encompassing R&D, manufacturing and commercial innovation, has enabled Lilly to lead advances in obesity and diabetes management globally.
Sanofi (USA)
Sanofi is another key player in the market that has commercialized GLP-1 combination drugs. Soliqua is an innovative, fixed-ratio combination of insulin glargine and the GLP-1 receptor agonist lixisenatide, specifically targeted at adults with type 2 diabetes. Unlike competitors that focus primarily on North America and Europe, Sanofi has a global presence, securing approval for Soliqua in more than 80 countries and actively expanding its reach in emerging markets, such as its recent launch in India (2024). Soliqua is recognized for solving the patient burden associated with multiple treatments by simplifying diabetes management by providing sustained glycemic control and minimizing weight gain through a convenient once-daily injection. The company focuses its R&D efforts on immunology and other complex disease areas, while also focusing on complex therapies and a strong supply chain infrastructure, giving it an edge in global distribution and accessibility. This establishes Sanofi as a key player in the diabetes treatment field, providing innovative GLP-1 solutions on a global scale.
Request a sample page: https://www.marketsandmarkets.com/requestsampleNew.asp?id=218746186
Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
manager: seed. Rohan Salgarcar
email: Send email
cell phone: 18886006441
address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
city: Florida
situation: Florida
nation: USA
Website: https://www.marketsandmarkets.com/Market-Reports/glp-1-analogues-market-218746186.html
Press Release Distributor: ABNewswire.com
To view the original version on ABNewswire, visit: GLP-1 agonists market will grow to USD 170.75 billion in 2033 at a CAGR of 13.0% | Market&Market™
